Natural Product (NP) Details

General Information of the NP (ID: NP6205)
Name
Asiatic acid
Synonyms
Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; MFCD00238541; NSC 166063; Asiantic acid; CHEBI:2873; CHEMBL404313; 9PA5A687X5; 2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic-acid; HSDB 7662; NSC-166063; Asiatic acid, 97%; SCHEMBL3285999; 2alpha,23-Dihydroxyursolic acid; Asiatic acid, analytical standard; DTXSID901019207; HY-N0194; ZINC8221271; BDBM50241487; AKOS007930256; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2.alpha.,3.beta.,4.alpha.)-; CCG-208549; DB14054; MCULE-1974040943; NCGC00346584-02; CS-0007893; N1356; V1794; C08617; 464A926; Q-100489; Asiatic acid, >=98% (HPLC), from Centella asiatica; BRD-K35079116-001-03-3; Q15478109; (2alpha,3beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4alpha)-2alpha,3beta,23-trihydroxy-urs-12-en-28-oic acid; (2alpha,3beta,5beta,20beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4I+/-)-a?I+/-,a?I(2),a?3-atrihydroxy-aurs-a?2-aen-a?8-aoic acid; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2alpha,3beta,4alpha)-; Urs-12en-28-oic acid, 2,3,23-trihydroxy-, (2alpha, 3beta, 4alpha)-; (1S,2R,4aS,6aS,6bR,8aR,9R,10R,11R,12aR,12bR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid; 0AS
    Click to Show/Hide
Species Origin Centella asiatica ...     Click to Show/Hide
Centella asiatica
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Apiales
Family: Apiaceae
Genus: Centella
Species: Centella asiatica
Disease Breast cancer [ICD-11: 2C60] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.572
 
MDCK Permeability
 -5.101
 
PAMPA
 +++
 
HIA
 - - -
 
Distribution
VDss
 -0.493
 
PPB
 79.1%
 
BBB
 +
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - - -
 
Excretion
CLplasma
 2.521
 
T1/2
 1.515
Toxicity
DILI
 +
 
Rat Oral Acute Toxicity
 - -
 
FDAMDD
 - -
 
Respiratory
 +
 
Human Hepatotoxicity
 +
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 +
 
Genotoxicity
 - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C30H48O5
PubChem CID
119034
Canonical SMILES
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C2C1C)C)C(=O)O
InChI
1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1
InChIKey
JXSVIVRDWWRQRT-UYDOISQJSA-N
CAS Number
CAS 464-92-6
ChEBI ID
CHEBI:2873
Herb ID
HBIN017057
SymMap ID
SMIT00254
TCMSP ID
MOL006861
TTD Drug ID
D0LC7K
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression p105  Molecule Info 
Pathway MAP
Up-regulation Expression SMAD7  Molecule Info 
Pathway MAP
                    In-vivo Model Twenty-four C57BL/6 male mice were used in this study
                    Experimental
                    Result(s)		 Asiatic acid protects against cisplatin-induced AKI via anti-apoptosis and anti-inflammation.
          Doxorubicin      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression AKT1  Molecule Info 
Pathway MAP
                    In-vitro Model H9c2(2-1) CVCL_0286 Healthy Rattus norvegicus
                    In-vivo Model Male C57BL/6 mice were used in this study.
                    Experimental
                    Result(s)		 Asiatic acid could attenuate DOX-induced myocardial oxidative stress and apoptosis via activation of the AKT signaling pathway.
Target and Pathway
Target(s) Myophosphorylase (PYGM)  Molecule Info  [4]
References
Reference 1 Asiatic Acid Interferes with Invasion and Proliferation of Breast Cancer Cells by Inhibiting WAVE3 Activation through PI3K/AKT Signaling Pathway. Biomed Res Int. 2020 Feb 10;2020:1874387.
Reference 2 Asiatic acid protects against cisplatin-induced acute kidney injury via anti-apoptosis and anti-inflammation. Biomed Pharmacother. 2018 Nov;107:1354-1362.
Reference 3 Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice. Oxid Med Cell Longev. 2020 May 15;2020:5347204.
Reference 4 Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link